Asset profile
PF-06865571
Unknown / undisclosed
Evidence outlook · lead readout
MIRNA (NCT04321031) · Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis With Liver Fibrosis
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
MIRNA (NCT04321031): The trial was randomized, double-blind/double-dummy, placebo-controlled, and included 256 participants, with liver-biopsy-based NASH and fibrosis outcomes as its primary endpoints. However, the two primary analyses were discordant: Bayesian dose-response comparisons for PF-06865571 alone were not clearly positive, whereas some combination-arm comparisons were favorable, so the results support moderate rather than strong evidence.
Also in development:Metabolic Dysfunction-Associated Steatohepatitis
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
36 competitors in this universe: 1 direct rival (same mechanism and indication), 0 same-class, 35 same-indication; 16 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| PF-06865571: this drug | Phase 2 | — | Diacylglycerol acyltransferase 2 (DGAT2) | ||
| PF-06865571 Monotherapy | Phase 2 | — | Diacylglycerol acyltransferase 2 (DGAT2) | ||
| Resmetirom (Rezdiffra) | Approved | Small molecule | Thyroid hormone receptor-beta | ||
| Rosuvastatin | Approved | Small molecule | HMG-CoA reductase | ||
| Semaglutide (Wegovy / Ozempic / Rybelsus) | Approved | Peptide | GLP-1 receptor | ||
| ALN-CIDEB | Phase 3 | RNA / oligonucleotide | CIDEB | ||
| Aramchol | Phase 3 | — | Stearoyl-CoA desaturase 1 (SCD1) | ||
| Denifanstat | Phase 3 | Small molecule | Fatty acid synthase (FASN), FASN | ||
| Efimosfermin | Phase 3 | Protein / enzyme therapeutic | FGF21 | ||
| Efimosfermin Alfa | Phase 3 | Protein / enzyme therapeutic | FGF21 receptor | ||
| Lanifibranor | Phase 3 | Small molecule | Peroxisome proliferator-activated receptors (PPARs), PPAR (pan-agonist) | ||
| Lobeglitazone (Duvie) | Phase 3 | Small molecule | PPAR-gamma | ||
| Namodenoson | Phase 3 | — | Adenosine A3 receptor | ||
| ORMD-0801 | Phase 3 | Peptide | Insulin receptor (basal) | ||
| Pemvidutide | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) | ||
| Survodutide | Phase 3 | Peptide | GLP-1/glucagon receptor (dual) |
…and 21 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.